---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-21-003829"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2021-08-23T23:59:59+00:00"
generated_at: "2026-06-29T08:19:43.418454+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte Biotech raises $70M in registered direct offering and private placement

## Summary
- Gross proceeds ~$70M from sale of 8.43M shares and 5.57M pre-funded warrants at $5.00 per share.
- Unregistered Series A warrants for 7M shares at $5.00, exercisable immediately, 5-year term.
- Net proceeds to address FDA clinical hold on IND for Phase 2b trial in pancreatic cancer and fund trial.
- H.C. Wainwright acting as exclusive placement agent; closing expected on or about August 23, 2021.

## SEC filing metadata
- accession: 0001683168-21-003829
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2021-08-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316821003829/0001683168-21-003829-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316821003829/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-21-003829
- JSON: https://secwatch.observer/filing/0001683168-21-003829.json
- Plain text: https://secwatch.observer/filing/0001683168-21-003829.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.